RGRX - RegeneRx Biopharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1500
-0.0098 (-6.13%)
At close: 3:21PM EDT
Stock chart is not supported by your current browser
Previous Close0.1598
Open0.1400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1400 - 0.1500
52 Week Range0.0700 - 0.3500
Volume6,400
Avg. Volume25,703
Market Cap19.726M
Beta (3Y Monthly)-0.35
PE Ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings DateNov 11, 2019 - Nov 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • PR Newswire

    RegeneRx Partner Updates on ARISE-3 Clinical Trial

    Enrollment on Target for Completion of Phase 3 Dry Eye Trial in Q2 2020 ROCKVILLE, Md. , Sept. 30, 2019 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), ...

  • PR Newswire

    RegeneRx to Present at Fall Investor Summit on September 17

    ROCKVILLE, Md., Sept. 10, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at the Fall Investor Summit on September 17, 2019, at 8:30 a.m. ET in New York City.  The presentation will be webcast and can be accessed by the following link:  https://www.webcaster4.com/Webcast/Page/2038/31564.  A slide presentation will also be available on the Company's website at:  http://www.regenerx.com/presentations. RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair and regeneration.

  • PR Newswire

    RegeneRx Modifies September Conference Schedule

    ROCKVILLE, Md., Sept. 4, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at The Fall Investor Summit on September 16-17, 2019, in New York City.  The specific presentation date, time and webcast information will be announced as soon as determined by the conference schedulers.  The Company will not be presenting at the Rodman & Renshaw Investment Conference on September 8-10 as was previously announced. RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair and regeneration.

  • PR Newswire

    First Patient Enrolled in RGN-137 Trial for Epidermolysis Bullosa Experiences Complete Wound Healing

    ROCKVILLE, Md., Aug. 5, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today confirmed that the first patient enrolled in a single-blinded, phase 2 clinical trial in patients with epidermolysis bullosa (EB) has positively responded to RGN-137, the Company's novel topically-administered drug candidate.

  • PR Newswire

    RegeneRx's RGN-137 for Epidermolysis Bullosa Subject of New Article in Seeking Alpha Investor Site

    ROCKVILLE, Md., July 29, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that RGN-137, the Company's wound healing product candidate currently the subject of a U.S. clinical trial, is the subject of an in depth article in Seeking Alpha, a financial website producing original reports and research covering a broad range of stocks, asset classes, ETFs and investment strategies.  The article describes the current clinical status of RGN-137, RegeneRx's out-licensing strategy, a description of epidermolysis bullosa, and a profile of its partner, GtreeBNT. The report can be viewed by clicking on the link that follows or by browsing RegeneRx's web site.

  • PR Newswire

    RegeneRx to Present at the Rodman & Renshaw and the Fall Investor Summit Conferences in September 2019

    ROCKVILLE, Md., July 16, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at the Rodman & Renshaw 21st Annual Global Investment Conference on September 8-10, 2019 and the Fall Investor Summit on September 16-17, 2019, both in New York City.  Specific presentation dates, times and webcast information will be announced in August. RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries throughout the world.

  • PR Newswire

    RegeneRx Licensee Administers RGN-137 to First Patient in Phase 2 EB Clinical Trial

    EB is a rare inherited connective tissue disease that causes blistering in the skin and in mucosal membranes resulting in difficult to treat wounds, skin fragility, and pain. EB is a serious disease with symptoms typically appearing in infancy and no available standard treatments beyond symptomatic relief.  There are an estimated 500,000 patients worldwide and 50,000 patients in both the U.S. and Europe where EB is designated an orphan disease.  The market size was approximately US$1.4 billion in 2017, according to Knowledge Sourcing Intelligence.

  • PR Newswire

    RegeneRx Receives Final Payment from Convertible Debt Financing

    ROCKVILLE, Md., May 28, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed the second closing and issuance of convertible promissory notes and received the final $650,000 from its convertible debt financing in February.  The second closing occurred upon enrollment of the first patient in the phase 3 dry eye trial (ARISE-3).  The proceeds will be used to fund planned operations while ARISE-3 and two other U.S. clinical trials are being conducted by its licensees, GtreeBNT and ReGenTree, LLC. The 5-year unregistered convertible notes carry a 5% simple interest rate that accrues during the term.  The aggregate proceeds received from the note placement was $1,300,000 and the notes are convertible into 10,833,333 of RGRX common stock at $0.12 per share.  As part of the transaction, the note holders received an aggregate of 8,125,000 warrants to purchase RGRX common stock at a price of $0.18 per share.

  • PR Newswire

    RegeneRx Partner Receives Patent for New Ophthalmic Formulation of Thymosin Beta 4

    ROCKVILLE, Md., May 16, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, reported today that its U.S. joint venture partner and Pan Asian licensee, GtreeBNT, has been granted a new U.S. patent for a method of preventing or treating dry eye syndrome by administering Tβ4 with non-active ingredients to provide improved pharmacodynamics.  Tβ4 is the active component of RGN-259, currently in separate phase 3 clinical trials for dry eye syndrome and neurotrophic keratitis.  The expiry of this new patent is 2035. Dry eye syndrome is a common condition affecting millions of people throughout the world.  It is a multi-factorial disorder where loss of homeostasis of the tear film results in pain, itching, blurry vision, and dryness, among other symptoms.

  • PR Newswire

    First Patient Enrolled in RegeneRx JV Phase 3 Dry Eye Trial

    ROCKVILLE, Md., May 13, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that the first patient has been enrolled in ARISE-3, a phase 3 clinical trial sponsored by ReGenTree LLC, a U.S. joint venture between RegeneRx and GtreeBNT, a Korean biopharmaceutical company.  The clinical trial will evaluate RGN-259, a sterile, preservative-free eye drop in 700 patients with dry eye syndrome (DES) at approximately fifteen nationwide clinical sites across the U.S., including hospitals and clinics specializing in ophthalmology, comparing the drug candidate to placebo.  Completion is expected during mid-2020. Additional information may be found at  clinicaltrials.gov/ct2/show/NCT03937882?term=arise-3&rank=1.

  • PR Newswire

    RegeneRx Publishes Annual Letter to Shareholders

    ROCKVILLE, Md., April 22, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published its annual letter to stockholders on the Company's website at www.regenerx.com. Any statements in this shareholder letter that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.

  • PR Newswire

    RegeneRx to Present at 2019 Spring Investor Summit

    ROCKVILLE, Md., March 27, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at the Spring Investor Summit taking place on April 1-2, 2019 in New York, NY.  Mr. Finkelstein will speak on Tuesday, April 2 at 9:00 a.m. ET.  A copy of his presentation will be available on the Company's website at http://www.regenerx.com/presentations on Tuesday morning. RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries throughout the world.

  • PR Newswire

    RegeneRx and Lee's Pharm to Accelerate RGN-259 Development in China

    ROCKVILLE, Md. and HONG KONG, March 26, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings Limited ("Lee's Pharm"), a Hong Kong-based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications.  Lee's Pharm previously licensed RGN-259, RegeneRx's sterile, preservative-free, topical eye drop developed for the treatment of ophthalmic indications such as dry eye syndrome (DES), neurotrophic keratitis (NK), and other persistent corneal disorders, in China, Taiwan, Macau, and Hong Kong.

  • PR Newswire

    RegeneRx Announces New Board Member

    ROCKVILLE, Md., March 21, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the appointment of Alessandro Noseda M.D. to the Company's Board of Directors, effective April 1, 2019.  He will be the sixth member of the Company's Board. Dr. Noseda is the Chief Scientific Officer of Leadiant Biosciences S.p.A. and has extensive scientific and medical experience in the global development of new medical technologies and drug products.  He has held numerous managerial positions with the R&D and marketing organizations of multinational pharmaceutical companies during his career.  Previously, Dr. Noseda was the Director of Scientific Office and Strategic Alliances with Sigma-Tau, where he managed key R&D projects and was involved in creating partnerships with Novartis and Debiopharm, among others.

  • PR Newswire

    RegeneRx Closes $1.3 Million Convertible Debt Financing

    ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed a $1.3 million convertible debt financing.  The funds will be used for operations over the next approximately 12 months while a phase 3 dry eye trial (ARISE-3), phase 3 neurotrophic keratitis trial (SEER-1), and epidermolysis bullosa open study are being conducted by its partner and licensee.

  • PR Newswire

    RegeneRx's U.S. Joint Venture Initiates Key Phase 3 Dry Eye Clinical Trial with RGN-259

    ROCKVILLE, Md., Feb. 12, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx, has executed an agreement with Ora, Inc., located in Andover, Massachusetts, for initiation of ARISE-3 to study ReGenTree's new drug, RGN-259, a sterile, preservative-free eye drop for the treatment of dry eye syndrome. ARISE-3 is a randomized double-masked, placebo-controlled phase 3 clinical trial that is based on the results of previous clinical trials, ARISE-1 and ARISE-2.

  • PR Newswire

    RegeneRx Update on Dry Eye and EB Clinical Trials

    ROCKVILLE, Md. , Jan. 4, 2019 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue ...

  • PR Newswire

    RegeneRx Partner Updates on Clinical Trials

    "Regarding progress on ARISE-3, the manufacturing of the investigational product for ARISE-3 has been completed and the protocol for the study has been finalized and is now ready for the study. Also, since funding for the ARISE-3 clinical study is progressing smoothly towards the final stage, we will do our best to inform you of ARISE-3 study initiation as soon as possible.